Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 17/20 | 0.50 |
| ▸ | WNT3 | P56703 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617502 | 0.90 | SFRP1 (0.64) | SFRP1WNT3 | |
| SCHEMBL4616243 | 0.90 | SFRP1 (0.48) | SFRP1WNT3SMN1; SMN2 | |
| SCHEMBL4615864 | 0.90 | ALDH1A1 (0.45) | SFRP1WNT3LMNAKDM4ERECQL | |
| SCHEMBL4614737 | 0.86 | SFRP1 (0.60) | SFRP1WNT3 | |
| SCHEMBL4619287 | 0.82 | ALDH1A1 (0.58) | SFRP1WNT3KDM4ERECQLSMN1; SMN2 | |
| SCHEMBL4616395 | 0.81 | SFRP1 (0.66) | SFRP1WNT3 | |
| SCHEMBL6101508 | 0.81 | SFRP1 (0.52) | SFRP1WNT3SMN1; SMN2 | |
| SCHEMBL4618246 | 0.81 | SFRP1 (0.67) | SFRP1WNT3 | |
| SCHEMBL4615963 | 0.81 | ALDH1A1 (0.57) | SFRP1WNT3SMN1; SMN2 | |
| SCHEMBL4617927 | 0.80 | SFRP1 (0.54) | SFRP1WNT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | SIMON FRASER UNIVERSITY (CA) | 2006-11-02 | — | — | US | disclosed |
| US-20050065139-A1 | Glycosidase inhibitors and methods of synthesizing same | MEDINNOVA PARTNERS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | STS, SCLY, MGAM | SFRP1 2109/4885WNT3 2110/4885LMNA 4251/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | SFRP1 1/4885WNT3 346/4885LMNA 4608/4885 |
| US-20050065139-A1 | Glycosidase inhibitors and methods of synthesizing same | STS, SCLY, MGAM | SFRP1 2162/4885WNT3 2546/4885LMNA 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.